Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease

Celeste Roney, Padmakar Kulkarni, Veera Arora, Peter Antich, Frederick Bonte, Aimei Wu, N. N. Mallikarjuana, Sanjeev Manohar, Hsiang Fa Liang, Anandrao R. Kulkarni, Hsing Wen Sung, Malladi Sairam, Tejraj M. Aminabhavi

Research output: Contribution to journalArticle

261 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

Original languageEnglish (US)
Pages (from-to)193-214
Number of pages22
JournalJournal of Controlled Release
Volume108
Issue number2-3
DOIs
StatePublished - Nov 28 2005

Fingerprint

Blood-Brain Barrier
Nanoparticles
Alzheimer Disease
Pharmaceutical Preparations
Amyloidogenic Proteins
tau Proteins
Neurofibrillary Tangles
Amyloid Plaques
Nervous System Diseases
Amyloid
Surface-Active Agents
Neurodegenerative Diseases
Atrophy
Dementia
Blood Proteins
Central Nervous System
Therapeutics

Keywords

  • Alzheimer's disease
  • Blood-brain barrier
  • Central nervous system
  • Nanoparticles
  • Targeted drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., ... Aminabhavi, T. M. (2005). Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. Journal of Controlled Release, 108(2-3), 193-214. https://doi.org/10.1016/j.jconrel.2005.07.024

Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. / Roney, Celeste; Kulkarni, Padmakar; Arora, Veera; Antich, Peter; Bonte, Frederick; Wu, Aimei; Mallikarjuana, N. N.; Manohar, Sanjeev; Liang, Hsiang Fa; Kulkarni, Anandrao R.; Sung, Hsing Wen; Sairam, Malladi; Aminabhavi, Tejraj M.

In: Journal of Controlled Release, Vol. 108, No. 2-3, 28.11.2005, p. 193-214.

Research output: Contribution to journalArticle

Roney, C, Kulkarni, P, Arora, V, Antich, P, Bonte, F, Wu, A, Mallikarjuana, NN, Manohar, S, Liang, HF, Kulkarni, AR, Sung, HW, Sairam, M & Aminabhavi, TM 2005, 'Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease', Journal of Controlled Release, vol. 108, no. 2-3, pp. 193-214. https://doi.org/10.1016/j.jconrel.2005.07.024
Roney, Celeste ; Kulkarni, Padmakar ; Arora, Veera ; Antich, Peter ; Bonte, Frederick ; Wu, Aimei ; Mallikarjuana, N. N. ; Manohar, Sanjeev ; Liang, Hsiang Fa ; Kulkarni, Anandrao R. ; Sung, Hsing Wen ; Sairam, Malladi ; Aminabhavi, Tejraj M. / Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. In: Journal of Controlled Release. 2005 ; Vol. 108, No. 2-3. pp. 193-214.
@article{09ad83aec6da4847ac93544781e6cce0,
title = "Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5{\%} of Americans over age 65, and 20{\%} over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.",
keywords = "Alzheimer's disease, Blood-brain barrier, Central nervous system, Nanoparticles, Targeted drug delivery",
author = "Celeste Roney and Padmakar Kulkarni and Veera Arora and Peter Antich and Frederick Bonte and Aimei Wu and Mallikarjuana, {N. N.} and Sanjeev Manohar and Liang, {Hsiang Fa} and Kulkarni, {Anandrao R.} and Sung, {Hsing Wen} and Malladi Sairam and Aminabhavi, {Tejraj M.}",
year = "2005",
month = "11",
day = "28",
doi = "10.1016/j.jconrel.2005.07.024",
language = "English (US)",
volume = "108",
pages = "193--214",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease

AU - Roney, Celeste

AU - Kulkarni, Padmakar

AU - Arora, Veera

AU - Antich, Peter

AU - Bonte, Frederick

AU - Wu, Aimei

AU - Mallikarjuana, N. N.

AU - Manohar, Sanjeev

AU - Liang, Hsiang Fa

AU - Kulkarni, Anandrao R.

AU - Sung, Hsing Wen

AU - Sairam, Malladi

AU - Aminabhavi, Tejraj M.

PY - 2005/11/28

Y1 - 2005/11/28

N2 - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

AB - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

KW - Alzheimer's disease

KW - Blood-brain barrier

KW - Central nervous system

KW - Nanoparticles

KW - Targeted drug delivery

UR - http://www.scopus.com/inward/record.url?scp=27744599588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744599588&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2005.07.024

DO - 10.1016/j.jconrel.2005.07.024

M3 - Article

C2 - 16246446

AN - SCOPUS:27744599588

VL - 108

SP - 193

EP - 214

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2-3

ER -